Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.6250
+0.0450 (7.76%)
Feb 20, 2026, 4:00 PM EST - Market closed

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Research and Development of Immunotherapies and Vaccines
14.97M802.00K44.70M268.00K4.82M
Research and Development of Immunotherapies and Vaccines Growth
1766.46%-98.21%16580.22%-94.44%-29.57%
Total
14.97M802.00K44.70M268.00K4.82M
Total Growth
1766.46%-98.21%16580.22%-94.44%-29.57%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
United Kingdom
14.97M802.00K44.70M268.00K4.82M
United Kingdom Growth
1766.46%-98.21%16580.22%-94.44%-29.57%
Total
14.97M802.00K44.70M268.00K4.82M
Total Growth
1766.46%-98.21%16580.22%-94.44%-29.57%
Source: S&P Global Market Intelligence.